As exemplary shown in Fig. 5A, MFC analyses revealed in both myeloma cell lines tested, single blockade of the TIGIT receptor resulted in enhanced CD3/CD28 stimulated PBMC cytotoxicity. This evidence concerns the gene CD28 and plasma cell myeloma.